ERBB2 and cancer: Trastuzumab binds to ECD IV of HER2 (Fig. 1b), and prevents HER2–HER3 heterodimerization and tyrosine phosphorylation of HER2, and thus, suppresses PI3K/Akt activity resulting in inhibition of cancer cell proliferation [35, 36].